The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1356
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved ceftaroline fosamil (Teflaro – Forest), an intravenous (IV) cephalosporin, for treatment of acute bacterial skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA), and for treatment of community-acquired bacterial pneumonia in adults. It is the first beta-lactam antibiotic approved for treatment of MRSA.

MECHANISM OF ACTION — Like other beta-lactams, ceftaroline binds to penicillin-binding proteins (PBPs), inhibiting cell wall synthesis. Unlike other currently available beta-lactams, it has a high affinity in vitro for PBP2a, a unique PBP encoded by the mecA gene in MRSA.1

STANDARD TREATMENT2Skin and Skin-Structure InfectionUncomplicated skin and skinstructure ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
Article code: 1356a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian